Clinical Trial: Phase II Seldar Pharma Investigational Medication for IBS-D
This study was received from the Digestive Health Brief, an electronic newsletter of the American College of Gastroenterology and summarized from the ClinicalTrials.gov listing for ASP 7147. ClinicalTrials.gov is an online database of the U.S. National Institutes of Health that indexes most clinical trials involving human subjects in the U.S. and many other countries throughout the world.
This Phase II study for Seldar Pharma investigational medication, ASP 7147 (300 mg. twice daily for 4 weeks or placebo) is seeking men and women ages 18-75 who have irritable bowel syndrome with diarrhea, and who are able to communicate with investigators and provide written consent.
Excluded from participation in this specific study are those with IBS with constipation (IBS-C) or mixed/alternating type (IBS-M, sometimes known as IBS-A ) and/or untreated lactose intolerance and/or history of alcohol or drug abuse in the past two years, and/or other clinical trial participation in the previous month and/or or “other significant disease or condition that may interfere with trial completion.”
The trial involves thirteen sites in nine U.S. states: Arizona, California, Florida, Massachusetts, Missouri, Nevada, North Carolina, Ohio and Texas. Most began recruiting volunteers in November 2013, although some are not yet recruiting. The study is expected to complete data collection by December 2014. For further information, see the listing linked in the first paragraph of this post.
Previous posts on open clinical trials for IBS can be found by clicking the clinical trials category in the blog archives on the upper right sidebar of this blog. We also have a page for IBS studies on the main IBS Impact site.The research and links pages and the July 26, 2011 post provide additional general resources.
We welcome researchers affiliated with academic, medical or pharmaceutical entities, or reputable organizations representing IBS or related or commonly overlapping conditions, to contact us directly with additional studies they wish to be considered for posting. Contact links for the founder/listowner and the webmaster can be found on the home page of the main IBS Impact website.
IBS Impact makes these study announcements available for general information, and encourages its members and site visitors to make their own individual, informed choices about their potential participation in any study. IBS Impact, as an entity, is not directly affiliated with any research sponsor and receives no funding from any source for studies or links we feature on this blog, the main site or social media.